All products
Overview ›
Breast Cancer ›
Endopredict®
Hereditary Cancer ›
Myriad myRisk® Hereditary Cancer
riskScoreTM
BRACAnalysis®
Colaris®
Colaris AP®
Prostate Cancer ›
Personalizing Prostate Cancer Treatment
Prolaris®
Precision Medicine ›
myChoice® CDx
BRACAnalysis CDx®
Melanoma ›
Myriad myPath® Melanoma

Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient’s increased cancer risk, disease aggressiveness, optimize efficacy of chemotherapy and identify patients’ most suitable for therapy.

To learn more about each of our products, simply click on a product logo below:

BREAST CANCER

EndoPredict® is the only test that answers the following three important clinical questions…

  • Can chemotherapy be avoided? (individual risk at 10 years1)
  • What is the absolute benefit from chemotherapy? (individual chemotherapy benefit2)
  • Can endocrine therapy be stopped after 5 years? (individual risk up to 15 years3)

… to optimize treatment for breast cancer patients.

HEREDITARY CANCER

Myriad myRisk® Hereditary Cancer is a 35-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer  syndromes, with focus on eight primary cancer sites.

riskScore® is a clinically validated algorithm that predicts a woman’s remaining 5-year and lifetime risk of developing breast cancer.

The BRACAnalysis® test assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.

COLARIS® testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine/endometrial cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6 and PMS2 genes.

COLARIS AP® testing assesses a person’s risk of developing hereditary colorectal polyps and cancer by detecting mutations in the APC and MYH genes.

PROSTATE CANCER

Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.

PRECISION MEDICINE

Learn more about myChoice CDx

BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).4,5,6

MELANOMA

Myriad myPath® Melanoma is a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone.

Sources:

  1. Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin Cancer Res. 2011; 17(18):6012-6020
  2. Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019; 176:377-386
  3. Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019;25:3865-3872
  4. Intended Use: BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.Results of the test are used as an aid in identifying breast and ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants, who are or may become eligible for treatment with Lynparza® (olaparib). Detection of deleterious or suspected deleterious germline BRCA variants by the BRACAnalysis CDx test in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. This assay is for professional use only and is to be performed only at 320 Wakara Way, Salt Lake City, UT 84108.
  5. For more detailed information about Lynparza and its safety and efficacy please go to lynparza.com
  6. For more detailed information about Zejula and its safety and efficacy please go to zejula.com

Lynparza is a registered trademark of the AstraZeneca group of companies, Zejula is a registered trademark of Tesaro, Inc.